The Liver Week 2021

PROGRAMThe Liver Week 2021    May 13-15, 2021

Basic Research Symposium 2 / 15:50-16:10

A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis

Tae Gyu Oh
Institution / Affiliation
Salk Institute for Biological Studies, USA
Research Associate
Research Interests
Single Cell technology for Liver Diseases
Metagenomics / Metabolomics for Liver Diseases
Machine Learning / Deep Learning for predicting Liver Diseases

Representative Publications

  1. Yoshihara E, O’Connor C, Gasser E, Wei Z, Oh TG, Tseng TW, Wang D, Cayabyab F, Dai Y, Yu RT, Liddle C, Atkins AR, Downes M, Evans RM. Immune evasive human islet-like organoids ameliorate diabetes. Nature. 2020. 586, 606-611.
  2. Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, Raffatellu M, Dorrestein PC, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin CB, Knight R, Downes M, Evans RM, Loomba R. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metab. 2020 Jun 30:S1550-4131(20)30306-5.
  3. Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu Q, Zhang T, Leblanc M, Liu S, He M, Waizenegger W, Gasser E, Schnabl B, Atkins A, Yu R, Knight R, Liddle C, Downes M, Evans RM. FXR regulates intestinal cancer stem cell proliferation. Cell. 2019 Feb 21;176(5):1098-1112.e18.
  4. Baek SM, Oh TG, Lagendijk AK, Sutton DL, Paterson S, Bower NI, Koltowska K, Baillie GJ, Simons C, Muscat GE, Harvey N, Smith KA, Hogan BM. The alternative splicing regulator Nova2 constrains vascular Erk signalling to limit specification of the lymphatic lineage. Dev Cell. 2019 Apr 22;49(2):279-292.e5.
  5. Oh TG*, Wang SC, Muscat GE*. Minireview: Therapeutic Implications of Epigenetic Signaling in Breast Cancer. Endocrinol. 2017 Jan 1;158(3):431-447. (*Joint corresponding author)
  6. Oh TG, Wang SC, Acharya BR, Goode JM, Graham JD, Clarke CL, Yap AS, Musact GE. The Nuclear Receptor, RORγ, Regulates Pathways Necessary for Breast Cancer Metastasis. EBioMedicine. 2016 Apr;6:59-72.
  7. Oh TG, Bailey P, Dray E, Smith AG, Goode J, Eriksson N, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Clarke CL, Grimmond S, Dowhan DH, Muscat GE. PRMT2 and RORγ expression are associated with breast cancer survival outcomes. Mol Endocrinol. 2014 Jul 28(7):1166-85.

Health Policy Forum / 14:50-15:10

The Political and Clinical Progress for Hepatitis C Virus Elimination in Taiwan: From Beginnings to Present

Jia-Horng Kao
Institution / Affiliation
Hepatitis Research Center, National Taiwan University Hospital, Taiwan
Chair Professor
Research Interests
Prevention, Natural History, Molecular Virology, Pathogenesis and Treatment of Chronic Viral Hepatitis and HCC

Representative Publications

  1. Su TH, Liu CJ, Tseng TC, Chou SW, Liu CH, Yang HC, Wu SJ, Chen PJ, Chen DS, Chen CL, Kao JH*. Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. Hepatology 2016; 63(3):721-30.
  2. Liao SH, Su TH, Jeng YM, Liang PC, Chen DS, Chen CH, Kao JH*. Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. Hepatology 2019; 2019;69:209-21.
  3. Tseng TC, Liu CJ, Hsu CY, Hong CM, Su TH, Yang WT, Chen CL, Yang HC, Huang YT, Fang-Tzu Kuo S, Liu CH, Chen PJ, Chen DS, Kao JH. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019 Dec;157(6):1518-1529.
  4. Tseng TC, Liu CJ, Chang CT, Su TH, Yang WT, Tsai CH, Chen CL, Yang HC, Liu CH, Chen PJ, Chen DS, Kao JH. HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. J Hepatol. 2020 Jun;72(6):1105-1111.
  5. Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. J Hepatol. 2020 May;72(5):839-846.

Health Policy Forum / 15:10-15:30

The Political and Clinical Progress for Hepatitis C Virus Elimination in Egypt: From Beginnings to Present

Imam Waked
Institution / Affiliation
National Liver Institute, Egypt
Professor of Medicine
Research Interests
Viral Hepatitis, Cirrhosis Complications, HCC, NASH

Representative Publications

  1. Blach S, et al. Impact of COVID-19 on global hepatitis C elimination efforts. J Hepatol. 2021 74: 31–36.
  2. Waked I, et al. Screening and Treatment Program to Eliminate Hepatitis C in Egypt. N Engl J Med, 2020, 382: 1166-74.
  3. Han G, et al. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology 2020: 72:198-212.
  4. Shiha G, et al. GES: A validated simple score to predict risk of HCC in patients with HCV-associated advanced liver fibrosis after oral antivirals. Liver Int 2020. 40:2828–2833.
  5. Elshaarawy O, et al. Intermediate stage HCC: a summary review. J Hepatocell Carcinoma. 2019; 6:105–117.
  6. Merle P, et al. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after failure of sorafenib: RELIVE, a phase-3 randomized trial. Lancet Gastroenterol Hepatol, 2019, 4:454-465.
  7. Cooke G, et al. Lancet Gastroenterology & Hepatology Commission: Accelerating the Elimination of Viral Hepatitis Lancet Gastroenterol Hepatol. 2019; 4:135-184.

Health Policy Forum / 15:30-15:50

The Political and Clinical Progress for Hepatitis C Virus Elimination in Australia: From Beginnings to Present

Gregory Dore
Institution / Affiliation
Kirby Institute, University of New South Wales Sydney, Australia
Professor and Head, Viral Hepatitis Clinical Research Program
Research Interests
Hepatitis C Clinical Epidemiology, Therapeutic and Elimination Strategies

Representative Publications

  1. Dore GJ, et al. Randomized trial of elbasvir/grazoprevir in persons with HCV receiving opioid agonist therapy (C-EDGE CO-STAR). Ann Intern Med 2016;165:625-634. (citations: 193, top 1%). First international randomized trial of DAA therapy in people with drug dependence.
  2. Grebely J, et al (Dore GJ, senior author). Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastro Hepatol 2018;3:153-161. First international trial of DAA therapy in people with ongoing injecting drug use (citations: 84, top 1%).
  3. Dore GJ, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol 2020;72:431-440. First randomized clinical trial of simplified monitoring of DAA therapy.
  4. Dore GJ, Martinello M, Alavi M, Grebely J. Global hepatitis C virus elimination by 2030: why not? Nature Medicine 2020;26:157-162. Commentary on key issues for hepatitis C elimination.
  5. Dore GJ, Trooskin S. People with hepatitis C who inject drugs – Underserved, not undeserving. N Engl J Med 2020;383:608-611. A “Perspective piece” that outlines the successful program of HCV treatment access for people who inject drugs in Australia and proposes strategies to enhance access in the United States.

Basic Research Symposium 1 / 11:40-12:00

Neutrophils in Alcohol-Associated Liver Disease

Bin Gao
Institution / Affiliation
Laboratory Chief of Liver Diseases
Research Interests
Immunological Aspects
Molecular Pathogenesis
Therapeutic Targets of Fatty Liver Diseases and Liver Cancer

Representative Publications

  1. He, Y., Rodrigues, R., Wang, X., Seo, W., Ma, J., Hwang, S., Trojnár, E., Mátyás, C., Ren, R., Feng, D., Pacher, P., Kunos, G., and Gao, B.: Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. Journal of Clinical Investigation 2021;131(3):e141513
  2. He, Y., Feng, D., Hwang, S., Mackowiak, B., Wang, X., Xiang, X., Rodrigues, R., Jin, M., Ren, T., Fu, F., Ait-Ahmed, Y., Xu, M., Liangpunsakul, S., and Gao, B.: Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IκBζ target genes in hepatocytes. Journal of Hepatology 2021 Accept
  3. Guillot, A., Guerri, L., Feng, D., Kim, S., Paloczi, J., He, Y., Schuebel, K., Dai, S., Liu, F., Pacher, P., Kisseleva, T., Qin, X., Goldman, D., Tacke, F., Gao, B.: Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin αvβ6 upregulation following liver injury. Journal of Clinical Investigation 2021 Accept
  4. Hwang, S., He, Y., Xiang, X., Seo, W., Kim, S., Ma, J., Ren, T., Park, S., Zhou, Z., Feng, D., Kunos, G., Gao, B.: Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 2020; 72(2):412-429
  5. Xiang, X., Feng, D., Hwang, S., Ren, T., Matyas, C., Wang, X., Mo, R., Shang, D., Trojnar, E., He, Y., Seo, W., Shah, V., Pacher, P., Xie, Q., Gao, B.: Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming of impaired regeneration pathways. Journal of Hepatology 2020; 72,736-745
  6. Guillot, A., Ren, T., Jourdan, T., Pawlosky, R., Han, E., Zhang, L., Koob, G., Gao, B.: Targeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking (PNAS Direct submission). Proceedings of the National Academy of Sciences of the USA 2019; 116(51):25974-25981
  7. Gao, Y., Zhou, Z., Kim, S., Ren, T., Seo, W., Guillot, A., Ding, Y., Wu, R., Shao, S., Wang, X., He, Y., Wang, W., Feng, D., Xu, M., Zhong, W., Zhou, Z., Niu, J., Gao, B.: Alcohol suppresses T cell energy metabolism and cytokine production in ALDH2-deficient mice and humans: Roles of acetaldehyde and corticosterone. Gut 2019; 68:1311-1322.

KASL Symposium 1 / 08:40-09:00

Personalized Medicine in NAFLD: From Genetics and Systems Biology

Silvia Sookoian
Institution / Affiliation
Institute of Medical Research IDIM-National Scientific and Technical Research Council (CONICET), School of Medicine University of Buenos Aires, Argentina
Head of Clinical & Molecular Hepatology Department
Vice-Chair of Institute of Medical Research, IDIM-CONICET
Research Interests
Molecular Mechanisms in Nonalcoholic Fatty Liver Disease

Representative Publications

  1. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Gut. 2020 Aug;69(8):1483-1491. doi: 10.1136/gutjnl-2019-318811.
  2. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. GUT 2015 May;64(5):800-12
  3. Genetic Variation in TM6SF2 and the Risk of Nonalcoholic Fatty Liver Disease and Histological Disease Severity. Sookoian S, Castaño GO, Scian R, Mallardi P, Fernández Gianotti T, Burgueño AL, San Martino J, and Pirola CJ. Hepatology 2015; 61(2):515-25.
  4. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Pirola CJ, Fernández Gianotti T, Burgueño AL, Rey-Funes M, Loidl CF, Mallardi P, San Martino J, Castaño GO, Sookoian S. Gut. 2013;62(9):1356-63.
  5. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Sookoian S, Pirola CJ. Hepatology. 2011 Jun;53(6):1883-94.
  6. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Sookoian S, Rosselli MS, Gemma C, Burgueño AL, Fernández Gianotti T, Castaño GO, Pirola CJ. Hepatology. 2010, 52(6):1992-2000
  7. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. J Lipid Res. 2009 Oct;50(10):2111-6.

KASL Symposium 1 / 09:20-09:40

Personalized Medicine in Autoimmune Hepatitis

SIG Forum 3 / 14:10-14:30

Management of Difficult Cases of Autoimmune Hepatitis and New Therapeutics

Atsumasa Komori
Institution / Affiliation
Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Japan
Director, Department of Treatment for Intractable Disease
Research Interests
Autoimmune Liver Disease, Cholestatic Liver Disease, Fatty Liver Disease, Hepatocarcinogenesis

Representative Publications

  1. Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 2020; 27:58-69.
  2. Yagi M, Matsumoto K, Komori A et al. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. Liver Int. 2020; 40: 926-933.
  3. Honda A, Tanaka A, Kaneko T, Komori A et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology 2019; 70:2035-2046.
  4. Komori A and Yatsuhashi H. Management of pruritus in liver cirrhosis. In The evolving landscape of liver cirrhosis management. (eds. Yoshiji H. and Kaji K.) 2019, pp151-158. Springer Singapore.
  5. Komori A. Innate immunity of the bile duct and its disorder. In Pathology of the Bile Duct. (ed Nakanuma Y.) 2017, pp25-37. Springer Singapore.
  6. Yamasaki K, Tateyama M, Abiru S, Komori A et al. Elevated Serum Levels of Wisteria floribunda Agglutinin-Positive Human Mac-2 Binding Protein Predict the Development of Hepatocellular Carcinoma in Hepatitis C Patients. Hepatology 2014; 60:1563-1570.
  7. Working Subgroup for Clinical Practice Guidelines for Primary Biliary Cirrhosis (Komori A et al). The intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Guidelines for the management of Primary Biliary Cirrhosis. Hepatol Res. 2014:44 Suppl S1; 71-90.

KASL Symposium 2 / 14:10-14:30

Clinical Implications of Novel Biomarkers of Hepatitis B Virus

Man-Fung Yuen
Institution / Affiliation
The University of Hong Kong, Hong Kong
Chair Professor
Research Interests
Prevention, Natural History, Serology, Virology and Treatment of Chronic Hepatitis B and C, and Hepatocellular Carcinoma

Representative Publications

  1. Mak LY, Wong DK, Pollicino T, Raimondo G, Hollinger FB, Yuen MF. Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology hepatocarcinogenesis and clinical significance. J Hepatol 2020;73:952-964.
  2. Fung J, Mak LY, Chan AC, Chok KS, Wong TC, Cheung TT, Dai WC, Sin SL, She WH, Ma KW, Seto WK, Lai CL, Lo CM, Yuen MF. Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. Hepatology 2020;3:818-28.
  3. Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, Lim YS, Cheng W, Sievert W, Visvanathan K, Ruby E, Liaw S, Yan R, Huang Q, Colonno R, Lopatin U. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol 2020;5:152-166
  4. Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, Lik Yuen Chan H, Yoon KT, Klinker H, Manns M, Petersen J, Schluep T, Hamilton J, Given BD, Ferrari C, Lai CL, Locarnini SA, Gish RG. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. Hepatology 2020;72:19-31.
  5. Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, Hwang SG, Nguyen T, Flores O, Hartman G, Liaw S, Lenz O, Kakuda TN, Talloen W, Schwabe C, Klumpp K, Brown N. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology 2019;156:1392-1403.
  6. Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet 2018;392(10161):2313-2324.
  7. Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers 2018;4:18035.

KASL Symposium 2 / 14:30-14:50

HBV-Host Genome Integration: How Can We Detect It and What Is Its Impact?

Thomas Tu
Institution / Affiliation
The University of Sydney and Westmead Hospital, Australia
Group Leader of Molecular Viral Hepatitis Pathogenesis
Research Interests
Molecular Mechanisms of Hepatitis B Virus (HBV) Infection Persistence and HBV DNA Integration
Long-Term Host-Virus Interactions and Their Roles in Disease Progression during Chronic HBV Infection
Early Stages of Liver Cancer Initiation and the Clonal Expansion of Phenotypically Altered Hepatocytes

Representative Publications

  1. Budzinska M., Shackel N.A., Urban, S., and Tu T.# (2018)
    Sequence Analysis of Integrated Hepatitis B Virus DNA during HBeAg-Seroconversion Emerging Microbes and Infections, Jul 2018, DOI: 110.1038/s41426-018-0145-7.
  2. Tu T.#, Budzinska M.A., Vondran F.W.R., Shackel N.A., and Urban S. (2018)
    Hepatitis B virus DNA integration occurs independent of intracellular viral replication in an NTCP-dependent in vitro infection model Journal of Virology, Jun 2018, DOI: 10.1128/JVI.02007-17.
  3. Tu, T.#, Budzinska, M.A., Shackel, N.A., and Urban S. (2017)
    HBV DNA integration: Molecular mechanisms and clinical implications Viruses, Apr 2017, DOI:10.3390/v9040075.
  4. Tu T.*, Zehnder B.*, Qu B., and Urban S.# (2020)
    De novo synthesis of Hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA JHEP Reports, DOI: 10.1016/j.jhepr.2020.100195.
  5. Tu, T., Mason, W.S., Clouston, A.D., McCaughan, G.W., Shackel, N.A., Yeh, M.M., Schiff, E.R., Ruszkiewicz, A.R., Chen, J.W., Harley, H.A.J., Stroeher, U.H., and Jilbert, A.R.# (2015)
    Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection Journal of Viral Hepatitis, Jan 2015, DOI:10.1111/jvh.12380.
  6. Tu T.#, Zehnder B., Qu B., Ni Y., Main N., Allweiss L., Dandri M., Shackel N.A., George, J., and Urban S. (2020)
    A novel method to precisely quantify Hepatitis B Virus covalently closed circular (ccc)DNA formation and maintenance Antiviral Research, DOI: 10.1016/j.antiviral.2020.104865.
  7. Tu T.#, Block J., Wang S., Cohen C., and Douglas M. (2020)
    The lived experience of chronic hepatitis B: a more complete view of its impact and why we need a cure Viruses, May 2020, DOI: 10.3390/v12050515.

Distinguished Lectures / 15:00-15:40

Progress and Challenges in Achieving Hepatitis B Virus Elimination

Fabien Zoulim
Institution / Affiliation
INSERM Unit 1052, Lyon University, Hospices Civils de Lyon, France
Head of Hepatology Department
Head of Viral Hepatitis Laboratory
Research Interests
Clinical and Translational Research on Hepatitis B
Hepatitis B cure
Mechanism of Viral Persistence
Characterization of New Targets for Antiviral Therapy
Evaluation of New Antivirals

Representative Publications

  1. Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65(4):683-91.
  2. Lebosse F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J Hepatol. 2017;66(5):897-909.
  3. Testoni B, Lebosse F, Scholtes C, Berby F, Miaglia C, Subic M, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70(4):615-25.
  4. Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827-44.
  5. Stadelmayer B, Diederichs A, Chapus F, Rivoire M, Neveu G, Alam A, et al. Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J Hepatol. 2020;73(1):40-51.
  6. Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, et al. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020;159(2):521-33 e9
  7. Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, et al. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatol Commun. 2020;4(1):8-20.

KLCA Symposium 2 / 11:10-11:30

Role of Systemic Therapy in Intermediate-Stage Hepatocellular Carcinoma

Masatoshi Kudo
Institution / Affiliation
Kindai University, Japan
Professor and Chairman
Research Interests
Diagnosis and Treatment for Hepatocellular Carcinoma

Representative Publications

  1. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y, on behalf of the TACTICS study group: Randomised, multicentre prospective trial of transarterial chemoembolization (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 69:1492-1501, 2020.
  2. Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL, on behalf of the APPLE Association: A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements. Liver Cancer 9:245-260, 2020.
  3. Kudo M: Better efficacy of ramucirumab in Japanese patients than in the global population with unresectable hepatocellular carcinoma. Liver Cancer 9:232-244, 2020.
  4. Kudo M: Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma. Liver Cancer 8:73-77, 2019.
  5. Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group: Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 3:424-432, 2018.
  6. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163-1173, 2018.
  7. Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y: Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 3:37-46, 2018.

KLCA Symposium 3 / 13:50-14:10

How to Optimize Sequencing of Systemic Treatment in Advanced Hepatocellular Carcinoma

Ann-Lii Cheng
Institution / Affiliation
National Taiwan University; National Taiwan University Cancer Center, Taiwan
Distinguished Chair Professor, President Emeritus
Research Interests
Basic and Translational Research in Hepatocellular Carcinoma

Representative Publications

  1. Ann-Lii Cheng*. Pursuing efficacious systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):95-96.(review)
  2. Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Juan Liu, Chen Huang, Sohail Mulla, Yulei Wang, Ho Yeong Lim, Andrew X. Zhu, Ann-Lii Cheng*. Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905.
  3. Shen YC, Hsu CL, Jeng YM, Ho MC, Ho CM, Yeh CP, Yeh CY, Hsu MC, Hu RH, Cheng AL*. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. J Hepatol. 2020 Mar;72(3):489-497.
  4. Cheng AL* Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020 Feb;72(2):307-319.
  5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173.
  6. Cheng AL*, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M; Investigators’ Study Group. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. J Hepatol. 2015 Oct;63(4):896-904.
  7. Cheng AL*, Kang YK, Chen ZD, Tsao CJ, Qin SK, Kim JS, Luo RC, Feng JF, Ye SG, Yang TS, Su JM, Sun Y, Liang HJ, Liu JW, Wang JJ, Tak WY, Pan HM, Burock K, Zou J, Voliotis D, Guen ZZ. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 Jan;10(1):25-34.

SIG Forum 2 / 11:10-11:30

Introduction of the Useful Big Database for Researchers in NAFLD

Donghee Kim
Institution / Affiliation
Stanford University, USA
Research Staff (Academic)
Research Interests
nonalcoholic fatty liver disease (NAFLD) and obesity-related gastrointestinal diseases, focusing on a population-based study.

Representative Publications

  1. Donghee Kim, Luis Miguel Vazquez‐Montesino, Andrew A Li, George Cholankeril, Aijaz Ahmed. Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease. Hepatology 2020;72(5):1556-1568 (First and Corresponding author)
  2. Donghee Kim, Peter Konyn, George Cholankeril, Robert J Wong, Zobair M Younossi, Aijaz Ahmed, Sammy Saab, Renumathy Dhanasekaran, Neil Mehta, Fasiha Kanwa, Hashem El-Serag. Decline in Annual Mortality of Hepatitis C Virus–Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. Gastroenterology 2020;159(4):1558-1560. E2 (First and Corresponding author)
  3. Donghee Kim, Luis Miguel Vazquez-Montesino, Jessica A Escober, Christopher T Fernandes, George Cholankeril, Rohit Loomba, Stephen A Harrison, Zobair M Younossi, Aijaz Ahmed. Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all-cause and cardiovascular mortality. American Journal of Gastroenterology 2020;115(9):1496-1504 (First and Corresponding author)
  4. Donghee Kim, Adeyinka C Adejumo, Eric R Yoo, Umair Iqbal, Andrew A Li, Edward A Pham, George Cholankeril, Jeffrey S Glenn, Aijaz Ahmed. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. Gastroenterology 2019;157(4):1055-1066. e11 (First and Corresponding author)
  5. Donghee Kim, Andrew A Li, Brandon J Perumpail, Chiranjeevi Gadiparthi, Won Kim, George Cholankeril, Jeffrey S Glenn, Stephen A Harrison, Zobair M Younossi, Aijaz Ahmed. Changing trends in etiology‐based and ethnicity‐based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology 2019;69(3):1064-1074 (First author)
  6. Donghee Kim, Andrew Li, Chiranjeevi Gadiparthi Muhammad, Ali, George Cholankeril, Jeffrey Glenn, Aijaz Ahmed. Changing Trends in Etiology-based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology 2018;55:1154-1163 (First author and Corresponding author)

SIG Forum 2 / 11:30-11:50

MAFLD and Cardiovascular Disease

Jian-Gao Fan
Institution / Affiliation
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China
Professor and Director
Research Interests
Relationship of Obesity, Type 2 Diabetes, Metabolic Syndrome and Chronic Liver Diseases, Basic and Clinical Research on Gut-Liver Axis, Clinical Epidemiology of Fatty Liver Disease

Representative Publications

  1. Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, Yang RX, Zeng J, Zhou HP, Fan JG*. Lipotoxic Hepatocyte-Derived Exosomal miR-192-5p Activates Macrophages via Rictor/Akt/FoxO1 Signaling in NAFLD. Hepatology. 2019;72(2):454-469.
  2. Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Fan JG*. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Aliment Pharmacol Ther. 2019;50(1):93-102.
  3. Zhao ZH, Xin FZ, Xue YQ, Hu ZM, Han YM, Ma FG, Zhou D, Liu XL, Cui AY, Liu ZS, Liu YX, Gao J, Pan Q, Li Y*, Fan JG*. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp Mol Med. 2019; 51(9):103.
  4. Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL, Pan Q, Zhou H*, Fan JG*. Sodium butyrate reduces high fat diet-induced NASH through upregulation of hepatic GLP-1R expression. Exp Mol Med. 2018; 50(12):157.
  5. Fan JG*, Kim SU, Wong Vincent WS*. New Trends on Obesity and NAFLD in Asia. J Hepatol, 2017; 67:862-873.
  6. Fan JG*, Farrell GC*. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009; 50(1):204-10.
  7. Fan JG*, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005; 43(3):508-14.

KASL Symposium 3 / 17:10-17:30

Current and Novel Treatment Strategies of Hepatic Encephalopathy

Rajiv Jalan
Institution / Affiliation
Institute for Liver and Digestive Health, UCL Medical School, UK
Professor of Hepatology
Research Interests
Acute Liver Failure and Artificial Liver Support
Inflammation and Immunobiology
Portal Hypertension and 0ther Complications of Cirrhosis

Representative Publications

  1. Arroyo V, Angeli P, Moreau R, Jalan R, Clària J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M; investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif). The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021 Mar;74(3):670-685. doi: 10.1016/j.jhep.2020.11.048. Epub 2020 Dec 7. PMID: 33301825.
  2. Kumar R, Kerbert AJC, Sheikh MF, Roth N, Calvao JAF, Mesquita MD, Barreira AI, Gurm HS, Ramsahye K, Mookerjee RP, Yu D, Davies NH, Mehta G, Agarwal B, Patch D, Jalan R. Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding. J Hepatol. 2021 Jan;74(1):66-79. doi: 10.1016/j.jhep.2020.06.010. Epub 2020 Jun 16. PMID: 32561318.
  3. Arroyo V, Moreau R, Jalan R. Acute-on-Chronic Liver Failure. N Engl J Med. 2020 May 28;382(22):2137-2145. doi: 10.1056/NEJMra1914900. PMID: 32459924.
  4. Engelmann C, Sheikh M, Sharma S, Kondo T, Loeffler-Wirth H, Zheng YB, Novelli S, Hall A, Kerbert AJC, Macnaughtan J, Mookerjee R, Habtesion A, Davies N, Ali T, Gupta S, Andreola F, Jalan R. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. J Hepatol. 2020 Jul;73(1):102-112. doi: 10.1016/j.jhep.2020.01.011. Epub 2020 Jan 24. PMID: 31987990.
  5. Sundaram V, Kogachi S, Wong RJ, Karvellas CJ, Fortune BE, Mahmud N, Levitsky J, Rahimi RS, Jalan R. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol. 2020 Mar;72(3):481-488. doi: 10.1016/j.jhep.2019.10.013. Epub 2019 Oct 25. PMID: 31669304; PMCID: PMC7183313.
  6. Sundaram V, Jalan R, Wu T, Volk ML, Asrani SK, Klein AS, Wong RJ. Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation. Gastroenterology. 2019 Apr;156(5):1381-1391.e3. doi: 10.1053/j.gastro.2018.12.007. Epub 2018 Dec 18. PMID: 30576643.
  7. Hadjihambi A, Harrison IF, Costas-Rodríguez M, Vanhaecke F, Arias N, Gallego- Durán R, Mastitskaya S, Hosford PS, Olde Damink SWM, Davies N, Habtesion A, Lythgoe MF, Gourine AV, Jalan R. Impaired brain glymphatic flow in experimental hepatic encephalopathy. J Hepatol. 2019 Jan;70(1):40-49. doi: 10.1016/j.jhep.2018.08.021. Epub 2018 Sep 8. Erratum in: J Hepatol. 2019 Mar;70(3):582. PMID: 30201461.

SIG Forum 5 / 17:10-17:30

Clinical, Histological, and Molecular Profiling of Different Stages of Alcohol-Related Steatohepatitis

Ramon Bataller
Institution / Affiliation
University of Pittsburgh, USA
Chief of Hepatology
Research Interests
Liver Fibrosis and the Mechanisms and Determinants of Mortality of Alcoholic Liver Disease

Representative Publications

  1. Parker P, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, Dhanda A, Arrese M, McCune A, Rowe IA, Schnabl B, Mathurin M, Shawcross D, Abraldes JG, Lucey MR, Garcia-Tsao G, Verna E, Brown Jr RS, Bosques-Padilla F, Vargas V, Louvet A, Holt AP, Bataller R. Trajectory of serum bilirubin predicts spontaneous recovery in a real-world cohort of patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2021 (in press).
  2. Massey V, Parrish A, Argemi J, Moreno M, Mello A, Garcia-Rocha M, Altamirano J, Gemma Odena G, Dubuquoy L, Louvet A, Martinez C, Adrover A, Affo S, Morales-Ibanez O, Sancho-Bru P, Millan C, Alvarado-Tapias E, Morales-Arraez D, Caballeria J, Mann J, Cao S, Sun Z, Shah VH, Cameron A, Mathurin P, Snider N, Villanueva C, Morgan TR, Guinovart J, Vadigepalli R, Bataller R. Integrated multi-omics reveals glucose use reprogramming and identifies a novel hexokinase in alcoholic hepatitis. Gastroenterology 2020 (in press).
  3. Jiegen C, Argemi J, Odena G, Ming-Jiang X, Cai Y, Massey V, Parrish A, Vadigepalli R, Altamirano J, Cabezas J, Gines P, Caballeria J, Snider N, Sancho-Bru P, Akira S, Rusyn I, Gao B, Bataller R. Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. Sci Reports 2020 (in press).
  4. Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, Hutmacher F, Lee S, Ventura-Cots M, Bosques-Padilla F, Verna EC, Abraldes JG, Brown, RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Tu XM, Eckmann L, Van der Donk WA, Young R, Lawley TD, Stärkel P, Pride D, Fouts DE, Schnabl B. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575:505-511.
  5. Argemi J, Latasa MU, Atkinson SR, Blokhin IO, Massey M, Gue JP, Cabezas J, Lozano JJ, Van Booven D, Bell A, Cao S, Vernetti LA, Arab JP, Ventura-Cots M, Edmunds LR, Fondevilla C, Stärkel P, Dubuquoy L, Louvet A, Odena G, Gomez JL, Aragon T, Altamirano J, Caballeria J, Jurzak MJ, Taylor DL, Berasain C, Wahlestedt C, Monga ST, Morgan MY, Sancho-Bru P, Mathurin P, Furuya S, Lackner C, Rusyn I, Shah VH, Thursz MR, Mann J, Avila MA, Bataller R. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nat Commun 2019; 10:3126 .
  6. Shah ND, Ventura-Cots M, Abraldes JG, Alboraie M, Alfadhli A, Argemi J, Badia-Aranda E, Soler EA, Barritt IV AS, Bessone F, Biryukova M, Carrilho FJ, Fernández MC, Guiridi AD, Kassas ME, Eng-Kiong T, Farias A, George J, Gui W, Harichander-Thurairajah P, Hsiang JC, Husić-Selimovic A, Isakov V, Karoney M, Kim W, Kluwe J, Kochhar R, Dhaka N, Costa PM, Pharm MN, Ono SK, Reis D, Rodil A, Domech CR, Sáez-Royuela F, Scheurich C, Siow W, Sivac-Burina N, Traquino ES, Some F, Spreckic S, Tan S, Vorobioff J, Wandera A, Wu P, Yakoub M, Yang L, Yu Y, Zahiragic N, Zhang C, Cortez-Pinto H, Bataller R. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol 2019; 17:2320-2329.
  7. Ventura-Cots M, Watts AE, Cruz-Lemini M, Shah ND, Ndugga N, McCann P, Barritt IV AS, Jain A, Ravi S, Fernandez-Carrillo C, Abraldes JG, Altamirano J, Bataller R. Colder weather and fewer sunlight hours increase alcohol consumption and alcoholic cirrhosis worldwide. Hepatology 2019; 69:1916-30

KLTS Special Lecture/ 11:50-12:20

Outcome of Liver Retransplantation Using Living Donor Grafts

Kaori Kuramitsu
Institution / Affiliation
Kobe University, Japan
Assistant Professor
Research Interests
Liver Regeneration, Liver Fibrosis, Liver Transplantation

Representative Publications

  1. An P, Kuramitsu K, Lai M, Popov Y. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis. Nat Commun 2020; 11(1): 2362
  2. Kuramitsu K et al. A multicenter Japanese survey assessing the long-term outcomes of liver retransplantation using living donor grafts. Transplantation 2020; 104(4): 754-61
  3. Kuramitsu K et al. Analysis of portal vein reconstruction technique with high-grade portal vein thrombus in living donor liver transplantation. Ann Transplant 2016; 21: 380-5
  4. Kuramitsu K et al. The incidence of posthepatectomy liver failure defined by the international study group of liver surgery among living donors. J Gastrointest Surg 2016; 20(4): 757-64
  5. Kuramitsu K et al. Severe post-transplant lymphoproliferative disorder after living donor liver transplantation. Hepatol Res 2015; 45(3): 356-62
  6. Kuramitsu K et al. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol 2013; 183(1): 182-94
  7. Kuramitsu K et al. Carbon monoxide enhances early liver regeneration in mice after hepatectomy. Hepatology 2011; 53(6): 2016-26

Special Interest Group Forum 4 / 15:00-15:20

Measurement of Hepatic Venous Pressure Gradient (HVPG) and Its Clinical Significance during TIPS or PARTO: Tips and Pitfalls

Hitoshi Maruyama
Institution / Affiliation
Juntendo University, Japan
Associate Professor
Research Interests
Liver cancer, Portal hypertension, Imaging diagnosis, IVR

Representative Publications

  1. Maruyama H, Takahashi M, Ishibashi H, Okugawa H, Okabe S, Yoshikawa M, Yokosuka O. Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int 29: 708-714, 2009
  2. Maruyama H, Ishibashi H, Takahashi M, Imazeki F, Yokosuka O. Effect of signal intensity from the accumulated microbubbles in the liver for differentiation of idiopathic portal hypertension from liver cirrhosis. Radiology 252: 587-594, 2009
  3. Maruyama H, Shimada T, Ishibashi H, Takahashi M, Kamesaki H, Yokosuka O. Delayed periportal enhancement: a characteristic finding on contrast ultrasound in idiopathic portal hypertension. Hepatol Int 6: 511-519, 2012
  4. Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol 108: 568-574, 2013
  5. Maruyama H, Kamezaki H, Kondo T, Sekimoto T, Shimada T, Takahashi M, Okugawa H, Yokosuka O. Effects of inferior mesenteric vein flow in patients with cirrhosis. Clin Gastroenterol Hepatol 11: 1648-1654, 2013
  6. Maruyama H, Sekimoto T, Yokosuka O. Role of Contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: Evidence from a 10-year experience. J Gastroenterol 51: 421-433, 2016
  7. Maruyama H, Kobayashi K, Kiyono S, Ogasawara S, Ooka Y, Suzuki E, Chiba T, Kato N. Left gastric vein-based noninvasive test for esophageal varices: a same-day comparison of portal hemodynamic assessment with endoscopic appearance. Clin. Transl. Gastroenterol 9: 154, 2018

Young Investigators of the Year Session / 12:00-12:30

Recent Epidemiology of HCC in the US

Ju Dong Yang
Institution / Affiliation
Cedars-Sinai Medical Center, USA
Assistant Professor of Medicine
Research Interests
My research program has been focused on clinical research of liver cancer. I conducted several population-based cohort studies to describe recent trends in liver cancer epidemiology in the United States. I published multiple outcome and modeling research papers on liver cancer. For the past several years, I have conducted several liver cancer biomarker studies. We reported that circulating tumor cells (CTCs) are detectable in liver cancer patients and are independent predictors of patient survival. My recent publication demonstrated that the GALAD score, derived from three HCC protein tumor markers (AFP-L3, AFP, and Des-carboxyprothrombin) is highly accurate for the detection of early-stage HCC.

Representative Publications

  1. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian V, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. Journal of the National Cancer Institute in press
  2. State-Level Hepatocellular Carcinoma Incidence and Association with Obesity and Physical Activity in the United States. Lee YT, Wang JJ, Luu M, Tseng HR, Rich NE, Lu SC, Nissen NN, Noureddin M, Singal AG, Yang JD. Hepatology in press
  3. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Hepatology. 2021 Jan;73(1):422-436
  4. New advances in the diagnosis and management of hepatocellular carcinoma. Yang JD, Heimbach JK. BMJ. 2020 Oct 26;371
  5. Factors Associated with Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis. Yang JD, Luu M, Singal AG, Noureddin M, Kuo A, Ayoub WS, Sundaram V, Kotler H, Kim IK, Todo T, Voidonikolas G, Brennan TV, Kosari K, Klein AS, Hendifar A, Lu SC, Nissen NN, Gong J. Journal of the National Comprehensive Cancer Network. 2020 Sep;18(9):1210-1220.
  6. Diabetes is Associated with Increased Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. Yang JD, Ahmed JD, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR. Hepatology. 2020 Mar;71(3):907-916.
  7. Hepatocellular carcinoma: A Global View. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. Nature Review Gastroenterology and Hepatology. 2019 Oct;16(10):589-604.

State-of-the-Art Lecture / 11:10-11:45

Novel Insights of Translational Research in Nonalcoholic Steatohepatitis Fibrosis

Scott Friedman
Institution / Affiliation
Icahn School of Medicine at Mount Sinai, USA
Fishberg Professor of Medicine and Dean for Therapeutic Discovery
Research Interests
Mechanisms of Hepatic Fibrosis and Cancer

Representative Publications

  1. Friedman SL, Roll FJ, Boyles J & Bissell DM. Hepatic lipocytes: The principal collagen‑producing cells of normal rat liver. Proceedings of the National Academy of Sciences, 82:8681‑8685, l985. PMID: 3909149.
  2. Narla G, Heath K, Reeves H, Li D, Giono LE, Narla J, Glucksman M, Kimmelman A, Eng FJ, Chan A, Ferrari A, Martignetti J and Friedman SL. Kruppel-like factor 6, a candidate tumor suppressor gene mutated in prostate cancer. Science, 294:2563-5, 2001. (in the top 1% of citations in its field according to the Essential Science IndicatorsSM). PMID: 11752579
  3. Hernández-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, Czaja MJ, Friedman SL. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology, 142(4):938-946, 2012. (Listed in Faculty of 1000 – top 2% of published articles). PMID22240484. PMC3439519.
  4. Zhang DY, Goossens N, Guo J, Tsai M-C, Chou HI, Altunkaynak C, Sangiovanni A, Ivarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, Llovet JM, Hoshida Y, and Friedman SL. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 65(10):1754-6, 2016. PMC4848165.
  5. Lee YA, Noon LA, Akat KM, Ybanez MD, Lee T-F, Berres M-L, Fujiwara N, Goossens N, Chou H, Parvin-Nejad F, Khambu B, Kramer EGM, Gordon R, Pfleger C, Germain D, John GR, Campbell KN, Yue Z, Yin X-M, Cuervo AM, Czaja MJ, Fiel MI, Hoshida Y, and Friedman SL. .Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Communications, 9(1):4962, 2018. PMC6251897.
  6. Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Fiel MI, Goossens N, Chou, H, Hoshida Y, Friedman SL. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 69:385-395, 2018. PMID: 29572095. PMC6054570.
  7. Amor C, Feucht J, Leibold J, Ho Y-J, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Xing Li X, Giavridis T, Kulick A, Houlihan S, Peerschke E, Friedman SL, Ponomarev V, Piersigilli A, Sadelain M, Lowe SW. Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 583: 127-132, 2020, PCMID PMC7583560.

KASL Symposium 5 / 15:00-15:15

MAFLD vs. NAFLD: What's in the Name? Pros: Not Just a Name Change

Jacob George
Institution / Affiliation
The University of Sydney, Australia

Representative Publications

  1. Eslam M, Sanyal AJ, George J. Toward more accurate nomenclature for fatty liver diseases. Gastroenterology 2019;157:590-593.
  2. Eslam M, Sanyal AJ, George J, on behalf of an international consensus panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999-2014.e1.
  3. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wong VWS, Dufour JF, Schattenberg J, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Jarvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J.  A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. Journal of Hepatology 2020;73(1):202-209.
  4. Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut 2020;69(8):1545-1547.
  5. Eslam M, Sarin SK, Wong VWS, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
    Hepatology International 2020 [Epub ahead of print] 12/10/2020.

KASL Symposium 5 / 15:15-15:30

MAFLD vs. NAFLD: What's in the Name? Cons: Premature Proposition

Ajay Duseja
Institution / Affiliation
Postgraduate Institute of Medical Education and Research, India
Research Interests
Nonalcoholic Fatty Liver Disease (NAFLD), Acute-on-Chronic Liver Failure (ACLF), Viral Hepatitis and Hepatocellular Carcinoma (HCC)

Representative Publications

  1. Duseja A, Taneja S. Changing Nomenclature from Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Fatty Liver Disease – Not Only Premature But Also Confusing. J Clin Exp Hepatol 2020;0.
  2. Duseja A, De A, Taneja S, Choudhury AK, Devarbhavi H, Hu J, et al. APASL ACLF Working Party, APASL ACLF Research Consortium (AARC). Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failure. Liver Int. 2021;41(1):150-157.
  3. Duseja A, Najmy S, Sachdev S, Pal A, Sharma RR, Marwah N, Chawla Y. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open. 2019 Jan 16;3(2):133-139.
  4. Duseja A, Acharya SK, Mehta M, Chhabra S; Shalimar, Rana S, Das A, Dattagupta S, Dhiman RK, Chawla YK. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol. 2019 Aug 7; 6(1):e000315.
  5. Nampoothiri RV, Duseja A, Rathi M, et al. Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. J Clin Exp Hepatol. 2019; 9:22-28.
  6. Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016; 31:213-21.
  7. Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015; 5:51-68.

KASL Symposium 5 / 15:40-15:55

Which Is the More Appropriate Surrogate and Target? Liver Fibrosis and/or Inflammation

Vincent Wong
Institution / Affiliation
The Chinese University of Hong Kong, Hong Kong
Research Interests
Epidemiology, Natural History, Non-Invasive Assessment and Treatment of Non-Alcoholic Fatty Liver Disease

Representative Publications

  1. Lee HW, …, Wong VW. Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. Hepatology 2020;72:1230-1241.
  2. Wang Y, …, Wong VW. Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. Gut 2020;69:1116-1126.
  3. Wong GL, …, Wong VW. Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. Hepatology 2019;70:971-981.
  4. Wong VW, Irles M, Wong GL, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut 2019;68:2057-2064.
  5. Yip TC, …, Wong VW. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol 2019;70:361-70.
  6. Wong VW, Wong GL, Chan RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol 2018;69:1349-56.
  7. Wong GL, …, Wong VW. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol 2018;69:793-802.

KASL-KAHBPS-KLCA-KLTS Joint Symposium / 09:10-09:30

Update of Treatment in Intrahepatic Cholangiocarcinoma: Resection and Transplantation

Gonzalo Sapisochin
Institution / Affiliation
Toronto General Hospital, University of Toronto, Canada
Abdominal Transplant and HPB Surgical Oncology
Research Interests
Liver Transplantation, Transplant Oncology, CRC Liver Metastases, Hepatocellular Carcinoma, Cholangiocarcinoma, Living Donor Liver Transplant

Representative Publications

  1. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities.
    Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V.Sapisochin G, et al. Ann Surg. 2021 Mar 1;273(3):483-493. doi: 10.1097/SLA.0000000000004071.Ann Surg. 2021. PMID: 33065633
  2. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma.
    Pinato DJ, Fessas P, Sapisochin G, Marron TU.Pinato DJ, et al. Among authors: sapisochin g. Hepatology. 2020 Dec 28. doi: 10.1002/hep.31697. Online ahead of print.
  3. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
    Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G.Gorgen A, et al. Among authors: sapisochin g. Transplantation. 2020 Oct;104(10):2087-2096.
  4. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.
    Goldaracena N, Gorgen A, Doyle A, Hansen BE, Tomiyama K, Zhang W, Ghanekar A, Lilly L, Cattral M, Galvin Z, Selzner M, Bhat M, Selzner N, McGilvray I, Greig PD, Grant DR, Sapisochin G.Goldaracena N, et al. Among authors: sapisochin g. J Hepatol. 2019 Apr;70(4):666-673
  5. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
    Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, Ghanekar A, Greig PD, McGilvray ID, Selzner M, Cattral MS, Grant DR, Lilly LB, Selzner N, Renner EL, Sherman M, Sapisochin G.Doyle A, et al. Among authors: sapisochin g. J Hepatol. 2019 May;70(5):866-873
  6. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.
    Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J; iCCA International Consortium.Sapisochin G, et al. Hepatology. 2016 Oct;64(4):1178-88.

KAHBPS Special Lecture / 14:10-14:40

Clinicopathological Characteristics of Intraductal Papillary Neoplasm of the Bile Duct (IPNB): Surgeons’ Point of View

Keiichi Kubota
Institution / Affiliation
Dokkyo Medical University, Japan
Professor, Director of Hospital
Research Interests
Hepatectomy for Liver Cirrhosis, Intraductal Papillary Neoplasm of the Bile Duct

Representative Publications

  1. Nakanuma Y, Uesaka K, Kakuda Y, Kubota K, et al. Intraductal papillary neoplasm of the bile duct: Updated clinicopathological characteristics and molecular and genetic alterations. J Clin Med (in press)
  2. Aoki T, Kubota K, Kubo S, Eguchi S,et al. Analysis of patient outcome after non-curative resection for hepatocellular carcinoma using nationwide survey data in Japan. World J Surg (in press)
  3. Kubota K, Jang JY, Nakanuma Y, Jang KT, et al. Evaluation of the clinicopathological characteristics of intraductal papillary neoplasm of the bile duct: a Japan-Korea collaborative study. J Hepatobiliary Pancreat Sci 2020; 27: 581-597.
  4. Matsumoto T, Kubota K, Hachiya H, Sakuraoka Y, et al. Impact of tumor location on postoperative outcome of intraductal papillary neoplasm of the bile duct. World J Surg 2019; 43: 1313-1322.
  5. Kubota K, Aoki T, Kumamaru H, Shiraki T, et al. Use of the National Clinical Database to evaluate the association between preoperative liver function and postoperative complications among patients undergoing hepatectomy. J Hepatobiliary Pancreat Sci 2019; 26: 331-340.
  6. Aoki T, Kubota K, Hasegawa K, Kubo S, et al. Significance of surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Br J Surg 2020; 107: 113-120.
  7. Kubota K, Nakanuma Y, Kondo F, Hachiya H, et al. Clinicopathological features and prognosis of mucin-producing bile duct tumor and mucinous cystic tumor of the liver: A multi-institutional study by the Japan Biliary Association. J Hepatobiliary Pancreat Sci 2014; 21: 176-185.

LCSGJ-KLCA Joint Symposium / 11:10-11:30

Hepatocellular Carcinoma Tumor Microenvironment

Yutaka Kurebayashi
Institution / Affiliation
Keio University, Japan
Research Associate/Instructor
Research Interests
Pathology of Hepatobiliary System, Pancreas, and Lung
Pathological Analysis of Tumor Immunology

Representative Publications

  1. Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018 Sep;68(3):1025-1041.
  2. Kurebayashi Y, Kubota N, Sakamoto M. Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications (Review). Hepatol Res. 2021 Jan;51(1):5-18.
  3. Kurebayashi Y, Emoto K, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H, Sakamoto M. Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator. Cancer Immunol Res. 2016 Mar;4(3):234-47.
  4. Kurebayashi Y, Olkowski CP, Lane KC, Vasalatiy OV, Xu BC, Okada R, Furusawa A, Choyke PL, Kobayashi H, Sato N. Rapid Depletion of Intratumoral Regulatory T cells Induces Synchronized CD8 T and NK Cell Activation and IFN-γ-dependent Tumor Vessel Regression. Cancer Res. 2021 doi: 10.1158/0008-5472.CAN-20-2673. Epub ahead of print.
  5. Morikawa R, Nakamoto N, Amiya T, Chu PS, Koda Y, Teratani T, Suzuki T, Kurebayashi Y, Ueno A, Taniki N, Miyamoto K, Yamaguchi A, Shiba S, Katayama T, Yoshida K, Takada Y, Ishihara R, Ebinuma H, Sakamoto M, Kanai T. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. J Hepatol. 2021 Mar;74(3):511-521.
  6. Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, Yamada T, Egami S, Hoshii T, Hirao A, Matsuda S, Koyasu S. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. Cell Rep. 2012 Apr 19;1(4):360-73.

KAHBPS Symposium 1 / 11:50-12:10

Transhepatic Hilar Approach for Perihilar Cholangiocarcinoma

Naohisa Kuriyama
Institution / Affiliation
Mie University Graduate School of Medicine, Japan
Assistant Professor
Research Interests
Basic Research:
Hepatic Ischemia Reperfusion Injury, Coagulation, and Inflammatory Pathways

  Clinical Research:
Highly Advanced Surgery and Neoadjuvant Chemotherapy for Cholangiocarcinoma
Laparoscopic HBP Surgery

Representative Publications

  1. Kuriyama N, Isaji S, Hamada T, Kishiwada M, Ohsawa I, Usui M, Sakurai H, Tabata M, Hayashi T, Suzuki K.
    The cytoprotective effects of addition of activated protein C into preservation solution on small-for-size liver graft in rats.
    Liver Transpl 2010; 16: 1-11.
  2. Kuriyama N, Duarte S, Hamada T, Busuttil RW, Coito AJ.
    Tenascin-c: A novel mediator of hepatic ischemia and reperfusion injury.
    Hepatology 2011; 54: 2125-2136.
  3. Kuriyama N, Isaji S, Kishiwada M, Ohsawa I, Hamada T, Mizuno S, Usui M, Sakurai H, Tabata M, Yamada T.
    Dual cytoprotective effects of splenectomy for small-for-size liver transplantation in rats. 
    Liver Transpl. 2012; 18: 1361-1370.

    Clinical Research:
  4. Kuriyama N, Isaji S, Tanemura A, Iizawa Y, Kato H, Murata Y, Azumi Y, Kishiwada M, Mizuno S, Usui M, Sakurai H.
    Transhepatic Hilar Approach for Perihilar Cholangiocarcinoma: Significance of Early Judgment of Resectability and Safe Vascular Reconstruction.
    J Gastrointest Surg. 2016;21:590-599.
  5. Kuriyama N, Usui M, Gyoten K, Hayasaki A, Fujii T, Iizawa Y, Kato H, Murata Y, Tanemura A, Kishiwada M, Sakurai H, Mizuno S, Isaji S. Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status.
    BMC Cancer. 2020;20:405.
  6. Kuriyama N, Kazuaki G, Hayasaki A, Fujii T, Iizawa Y, Kato H, Murata Y, Tanemura A, Kishiwada M, Sakurai H, Isaji S, Mizuno S. Surgical Procedures of Portal Vein Reconstruction for Recipients With Portal Vein Thrombosis in Adult-to-Adult Living Donor Liver Transplantation.
    Transplant Proc. 2020;52:1802-1806.
  7. Kuriyama N, Maeda K, Komatsubara H, Shinkai T, Noguchi D, Gyoten K, Hayasaki A, Fujii T, Iizawa Y, Murata Y, Tanemura A, Kishiwada M, Sakurai H, Mizuno S.
    The usefulness of modified splenic hilum hanging maneuver in laparoscopic splenectomy, especially for patients with huge spleen: a case-control study with propensity score matching.
    Surg Endosc. 2021 Feb 16.

KASL-KAHBPS-KLCA-KLTS Joint Symposium / 08:30-08:50

Histological and Molecular Characterization of Intrahepatic Cholangiocarcinoma

Mina Komuta
Institution / Affiliation
International University of Health and Welfare School of Medicine, Japan
Associate Professor
Research Interests
Tumour heterogeneity in hepato-biliary-pancreatic malignancy. To establish a pattern recognition pathological approach in non-tumoral liver diseases such as hepatitis. Hepatoblastoma.

Representative Publications

  1. Nakanuma Y, Klimstra DS, Komuta M, Zen Y. Intrahepatic cholangiocarcinoma. Digestive System Tumours (5th Edition) WHO Classification of Tumours, 2019 p254-259 ISBN-13: 978-9283244998
  2. Baldin P, Van den Eynde M, Mlecnik B, Bindea G, Beniuga G, Carrasco J, Haicheur N, Marliot F, Lafontaine L, Fredriksen T, Lanthier N, Hubert C, Navez B, Huyghe N, Pagès F, Jouret-Mourin A, Galon J, Komuta M. Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore. J Pathol Clin Res. 2020 Sep 9:e178.
  3. Komuta M, Yeh MM. A Review on the Update of Combined Hepatocellular Cholangiocarcinoma. Semin Liver Dis. 2020 May;40(2):124-130.
  4. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Park YN, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 2018 Jul;68(1):113-126
  5. Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, Katoonizadeh A, Wouters J, van Kempen LC, Durnez A, Verslype C, De Kock J, Rogiers V, van Grunsven LA, Topal B, Pirenne J, Vankelecom H, Nevens F, van den Oord J, Pinzani M, Roskams T. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut. 63(4):674-‐85. 2014
  6. Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenbergen W, Verslype C, Laleman W, Pirenne J, Aerts R, Yano H, Nevens F, Topal B, Roskams T. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 55(6):1876-‐88. 2012
  7. Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, Desmet VJ, Kojiro M, Roskams T. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 47(5):1544-‐56. 2008